Skip to main content
SpringerLink
Log in

Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response

  • Original Articles
  • Phenotypic Analysis, 1-β-d-Arabinofuranosylcytosine, Deamination, Ara C
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Two phenotypes for 1-B-d-arabinofuranosylcytosine (ara-C) deamination corresponding to a ratio of distribution for “slow” (ratio, ≤14) vs “fast” (ratio, >14) deaminators of 70%∶30%, have been determined on the basis of studies on plasma ratios of 1-B-d-arabinofuranosyluracil/ara-C (ara-U/ara-C) in 56 subjects treated with high-dose ara-C (3 g/m2 infused i.v. over 3 h). A positive correlation of age with the concentration of ara-U was observed. In a subgroup of 36 patients with leukemia, the ara-U/ara-C pattern was similar to that observed for all 56 subjects. In these leukemic patients, who were treated with combinations of ara-C plus other conventional agents, a tendency toward a positive response (complete response +partial response) was found for those showing low ara-U/ara-C ratios (slow deaminators). The phenotypic effect of deamination in acute leukemia needs to be evaluated prospectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bolwell BJ, Cassileth PA, Gale RP (1988) High dose cytarabine: a review. Leukemia 2:253–260

    Google Scholar 

  2. Camiener GW, Smith CG (1965) Studies of the enzymatic deamination of cytidine arabinoside I. Biochem Pharmacol 14:1405–1416

    Google Scholar 

  3. Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC (1983) Alteration of the pharmacokinetics of high dose ara-C by its metabolite, high ara-U, in patients with acute leukemia. J Clin Oncol 1:763–771

    Google Scholar 

  4. Chambers JM, Cleveland WS, Kleiner B, Tukey PA (1983) Graphical methods for data analysis. Wadsworth International Group, Belmont, California

    Google Scholar 

  5. Chou TC, Arlin Z, Clarkson BC, Philips FS (1977) Metabolism of 1-B-d-arabinofuranosylcytosine in human leukemic cells. Cancer Res 37:3561–3570

    Google Scholar 

  6. Coleman CN, Johns DG, Chabner BA (1975) Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells. Ann NY Acad Sci 255:247–251

    Google Scholar 

  7. DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S (1992) Pharmacokinetics of ara-C and ara-U in plasma and CSF after highdose administration. Cancer Chemother Pharmacol 29:173–177

    Google Scholar 

  8. Furner RL, Mellett LB, Herren TC (1975) Influence of tetrahydrouridine on the phosphorylation of 1-B-d-arabinofuranosylcytosine (ara-C) by enzymes from solid tumors in vitro. J Pharmacol Exp Ther 194:103–110

    Google Scholar 

  9. Harris AL, Graham-Smith DG (1982) The relationship of ara-C metabolism in vitro to therapeutic response in acute myeloid leukemia. Cancer Chemother Pharmacol 9:30–35

    Google Scholar 

  10. Ho DHW (1973) Distribution of kinase and deaminase of 1-B-d-arabinofuranosylcytosine in tissue of man and mouse. Cancer Res 33: 2816–2820

    Google Scholar 

  11. Ho DHW, Frei E (1971) Clinical Pharmacology of 1-B-d-arabinofuranosylcytosine (ara-C). Clin Pharmacol Ther 12:944–954

    Google Scholar 

  12. Kessel D, Shurin S (1968) Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a subline of the L1210 murine leukemia. Biochim Biophys Acta 163:179–187

    Google Scholar 

  13. Kreis W, Arlin Z, Budman D, Allen S, Schulman P, DeAngelis L, Lesser M, Baskind P, Feldman EJ, Akerman S (1991) Phenotypic analysis of deamination of ara-C in patients treated with high dose ara-C (HiDAC). Proc Am Assoc Cancer Res 32:176

    Google Scholar 

  14. Kreis W, Budman DR, Chan K, Allen SL, Schulman P, et al (1991) Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase) —a pilot study. Leukemia 5:991–998

    Google Scholar 

  15. Major P, Egan EM, Beardsley GP, Minden MD, Kufe DW (1981) Lethality of human myeloblasts correlates with the incorporation of ara-C into DNA. Proc Natl Acad Sci USA 78:3235–3239

    Google Scholar 

  16. Meyer UA, Zanger UM, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. Advances in drug research. 19: 197–241

    Google Scholar 

  17. Muller WEG, Zahn RK (1979) Metabolism of 1-B-d-arabinofuranosyluracil in mouse L5178Y cells. Cancer Res 39:1102–1107

    Google Scholar 

  18. Nelson RL, Povey S, Hopkinson DA, Harris H (1977) Detection after electrophoresis of enzymes involved in ammonia metabolism usingl-gentamate dehydrogenase as a linking enzyme. Biochem Genet 15:1023–1035

    Google Scholar 

  19. Piall EM, Aherne GW, Marks VM (1979) A radioimmunoassay for cytosine arabinoside. Br J Cancer 40:548–556

    Google Scholar 

  20. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ (1987) Saturation of 1-B-d-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high dose 1-B-d-arabinofuranosylcytosine therapy. Cancer Res 47: 3005–3011

    Google Scholar 

  21. Prooijen HC van, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br J Haematol 57:291–299

    Google Scholar 

  22. Riva CH, Barra Y, Cano JP, Tubiana N, Lejeune C, Merlin M, deSousa G, Carcassonne Y, Kreis W, Lovecchio J, Rottach C, Rustum YM (1990) Correlation between deoxycytidine kinase and deaminase activities and response to therapy with ara-C. J Cell Pharmacol 1:79–95

    Google Scholar 

  23. Rustum YM, Preisler HD (1979) Correlation between leukemic cell retention of ara CTP and response to therapy. Cancer Res 39:42–49

    Google Scholar 

  24. Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrozosek C, Early AP, Preisler H (1982) Relationship between plasma ara-C and intracellular ara CTP pools under conditions of continuous infusion and high dose ara-C treatment. Med Pediatr Oncol [Suppl] 1:33–43

    Google Scholar 

  25. SAS Procedures Guide for Personal Computers, Version 6. SAS Institute, Cary, North Carolina, pp 350–351

  26. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmacokinetics of high dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1:546–551

    Google Scholar 

  27. Stuart DC, Burke PJ (1971) Cytidine deaminase and development of resistance to arabinosylcytosine. Nature New Biol 233:109–110

    Google Scholar 

  28. Talley RW, O'Bryan RM, Tucker WG, Loo RV (1967) Clinical pharmacology and human antitumor activity of cytosine arabinoside. Cancer 20:809–816

    Google Scholar 

  29. Teng YS, Anderson J, Giblett E (1975) Cytidine deaminase: a new genetic polymorphism demonstrated in human granulocytes. Am J Hum Genet 27:492–497

    Google Scholar 

  30. Yang JL, Cheng EH, Capizzi RL, Cheng YC, Kute T (1985) Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. J Clin Invest 75:141–146

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, North Shore University Hospital and Cornell University Medical College, 300 Community Drive, 11030, Manhasset, New York, USA

    W. Kreis, M. Lesser, D. R. Budman, Z. Arlin, L. DeAngelis, P. Baskind, E. J. Feldman & S. Akerman

  2. Department of Research, North Shore University Hospital and Cornell University Medical College, 11030, Manhasset, New York, USA

    W. Kreis, M. Lesser, D. R. Budman, Z. Arlin, L. DeAngelis, P. Baskind, E. J. Feldman & S. Akerman

  3. New York Medical College, 10595, Valhalla, New York, USA

    W. Kreis, M. Lesser, D. R. Budman, Z. Arlin, L. DeAngelis, P. Baskind, E. J. Feldman & S. Akerman

  4. Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA

    W. Kreis, M. Lesser, D. R. Budman, Z. Arlin, L. DeAngelis, P. Baskind, E. J. Feldman & S. Akerman

Authors
  1. W. Kreis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Lesser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. R. Budman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z. Arlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. DeAngelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Baskind
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. J. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Akerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by the Don Monti Memorial Research Foundation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kreis, W., Lesser, M., Budman, D.R. et al. Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemother. Pharmacol. 30, 126–130 (1992). https://doi.org/10.1007/BF00686404

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686404

Keywords

Search

Navigation